This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biosimilars In Emerging Economies - Advanced Recombinant Technology Platforms And Low Cost Manufacturing Put India And China At A Strategic Advantage In Biosimilar Production

Table 16: Biosimilars in Emerging Economies, Pipeline Molecules, Lupin, 2012 39

Table 17: Biosimilars in Emerging Economies, Pipeline Molecules, Cipla, 2012 40

Table 18: Biosimilars in Emerging Economies, China, Revenue ($bn), 2002–2011 41

Table 19: Biosimilars in Emerging Economies, China, Revenue Forecasts ($bn), 2011–2018 41

Table 20: Biosimilars in Emerging Economies, Marketed Biosimilar Products, China, 2012 42

Table 21: Biosimilars in Emerging Economies, Marketed Biosimilar Products, 3SBio, 2012 43

Table 22: Biosimilars in Emerging Economies, Pipeline Molecules, 3SBio, 2012 44

Table 23: Biosimilars in Emerging Economies, Marketed Biosimilar Products, CPGJ, 2012 45

Table 24: Biosimilars in Emerging Economies, Pipeline Molecules, CPGJ, 2012 45

Table 25: Biosimilars in Emerging Economies, Marketed Biosimilar Products, Biotech Pharma, 2012 46

Table 26: Biosimilars in Emerging Economies, Pipeline Molecules, Filed, 2011 60

Table 27: Biosimilars in Emerging Economies, Pipeline Molecules, Phase III, 2011 60

Table 28: Biosimilars in Emerging Economies, Pipeline Molecules, Phase II, 2011 62

Table 29: Biosimilars in Emerging Economies, Pipeline Molecules, Phase I, 2011 62

Table 30: Biosimilars in Emerging Economies, Pipeline Molecules, Pre-clinical, 2011 63

Table 31: Biosimilars in Emerging Economies, Pipeline Molecules, Discovery, 2011 65

Table 32: Biosimilars in Emerging Economies, Pipeline Molecules, IND Filed, 2011 66

Table 33: Biosimilars in Emerging Economies, Pipeline Molecules, Unknown Phase, 2011 66

Table 34: Biosimilars in Emerging Economies, M&A by Year, 2007–2011 74

Table 35: Biosimilars in Emerging Economies, M&A by Value ($m), 2007–2011 75

Table 36: Biosimilars in Emerging Economies, M&A Deals, 2007–2011 76

Table 37: Biosimilars in Emerging Economies, Licensing Agreements, 2007–2011 78

Table 38: Biosimilars in Emerging Economies, Co-developments, 2007–2011 80

 

 

 

List of Figures

 

Figure 1: Biosimilars in Emerging Economies, EPO Biosimilars Marketed Outside the US and EU, 2011 12

Figure 2: Biosimilars in Emerging Economies, G-CSF Biosimilars Marketed Outside the US and EU, 2011 13

6 of 8

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,039.49 +60.36 0.36%
S&P 500 1,992.37 +5.86 0.30%
NASDAQ 4,532.1040 +5.6220 0.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs